Latest
April 30, 2013
On 24 April 2013, Minister of Trade and Industry Rob Davies stated that South Africa’s new intellectual property (IP) policy would not be released for public comment any time soon. This starkly contrasts with a number of promises in the past two years, by both the Minister and officials in the Department of Trade and […]
READ MORE
April 23, 2013
By Marcus Low This article was originally published on GroundUp on April 10 2013. The original article can be accessed here A treaty that has the potential to change the lives of millions of blind people is at risk of being hijacked by publishers who show no sympathy for the difficulties faced by blind people […]
READ MORE
April 12, 2013
TAC joins global actions against the European Union’s on-going efforts to restrict access to affordable medicines. The EU and India are in the final stages of negotiations for an EU-India free trade agreement (FTA). EU is also currently negotiating FTAs with Egypt, Morocco, Tunisia, Thailand, Vietnam and Malaysia. The EU has repeatedly attempted to use these […]
READ MORE
April 10, 2013
Professor Brook K. Baker, Senior Policy Analyst Health GAP April 2, 2013 Novartis, its fellow Big Pharma multinationals, Chambers of Commerce, and PhRMA have all roundly denounced India’s Supreme Court’s decision invalidating Novartis’ patent application for Glivec (Gleevec in the United States) and its affirmation of strict anti-evergreening standards of patentability and inventive step in […]
READ MORE
April 5, 2013
The 2012/2013 South African Health Review was launched on 2 April 2013. The first chapter of the publication reviews ‘Health policy and legislation’ in the country. The chapter includes a useful analysis of the draft intellectual property policy for South Africa, as well as the ruling in the recent docetaxel case. The chapter, which has […]
READ MORE
April 2, 2013
For the past 7 years, the Indian government has faced on-going court challenges and bullying by the pharmaceutical company Novartis. Novartis’s challenge has centred on provisions in the Indian Patents Act that exclude new uses and formulations of existing medicines from patentability. Specifically, Novartis challenged India’s rejection of its patent application for the cancer medicine […]
READ MORE
March 27, 2013
As the 5th BRICS Summit kicks off today in Durban, the South African government must follow the lead of its BRICS peers to ensure that life-saving medicines are affordable. Other BRICS countries have fulfilled the commitments they made in July 2011 to enact public health safeguards spelled out in World Trade Organisation (WTO) agreements. Decisive […]
READ MORE
March 19, 2013
By Mara Kardas-Nelson This article was originally published in the Mail&Guardian on 15 March 2013. The original is available at http://mg.co.za/article/2013-03-15-a-shocking-disregard-for-generics Many drugs cost far more in South Africa than in countries with strict patent-vetting processes. Two thousand four hundred and forty-two. That’s the number of medicine patents South Africa granted in 2008. In Brazil, […]
READ MORE
February 27, 2013
Photographs from the TAC/MSF picket at Gallagher Estate, directed at the Department of Trade and Industry (DTI), can be found here. The picket took place on 26 February 2013 during the DTI’s ‘AFrica IP Forum’.
READ MORE
27 February, MIDRAND – Yesterday, TAC activists picketed at the Africa Intellectual Property (IP) Forum and handed over a memorandum to Rob Davies, Minister of Trade and Industry, before his keynote address. Activists were demanding that the draft IP policy, that will lead to patent law reform, be made public. Minister Davies responded that the […]
READ MORE
Page 10 of 16« First«...89101112...»Last »
Globally people are suffering and dying needlessly because governments are unable to afford to buy medicines to save their lives. It is time to Fix the Patent Laws to save our lives!
Latest
DTI reneges on IP policy commitments
On 24 April 2013, Minister of Trade and Industry Rob Davies stated that South Africa’s new intellectual property (IP) policy would not be released for public comment any time soon. This starkly contrasts with a number of promises in the past two years, by both the Minister and officials in the Department of Trade and […]
READ MOREEnding the book famine for the blind
By Marcus Low This article was originally published on GroundUp on April 10 2013. The original article can be accessed here A treaty that has the potential to change the lives of millions of blind people is at risk of being hijacked by publishers who show no sympathy for the difficulties faced by blind people […]
READ MORETAC tweets photo messages to @EU_Commission in protest of the EU’s efforts to block access to affordable medicine
TAC joins global actions against the European Union’s on-going efforts to restrict access to affordable medicines. The EU and India are in the final stages of negotiations for an EU-India free trade agreement (FTA). EU is also currently negotiating FTAs with Egypt, Morocco, Tunisia, Thailand, Vietnam and Malaysia. The EU has repeatedly attempted to use these […]
READ MOREDebunking Pharma’s Cant Against the Novartis Judgment: Myth and Fact
Professor Brook K. Baker, Senior Policy Analyst Health GAP April 2, 2013 Novartis, its fellow Big Pharma multinationals, Chambers of Commerce, and PhRMA have all roundly denounced India’s Supreme Court’s decision invalidating Novartis’ patent application for Glivec (Gleevec in the United States) and its affirmation of strict anti-evergreening standards of patentability and inventive step in […]
READ MOREThe 2012/2013 South African Health Review provides an analysis of the draft IP policy
The 2012/2013 South African Health Review was launched on 2 April 2013. The first chapter of the publication reviews ‘Health policy and legislation’ in the country. The chapter includes a useful analysis of the draft intellectual property policy for South Africa, as well as the ruling in the recent docetaxel case. The chapter, which has […]
READ MOREIndia’s Supreme Court upholds the right to medicine
For the past 7 years, the Indian government has faced on-going court challenges and bullying by the pharmaceutical company Novartis. Novartis’s challenge has centred on provisions in the Indian Patents Act that exclude new uses and formulations of existing medicines from patentability. Specifically, Novartis challenged India’s rejection of its patent application for the cancer medicine […]
READ MORESouth Africa must follow BRICS peers’ lead: fix our dysfunctional patent system & protect public health
As the 5th BRICS Summit kicks off today in Durban, the South African government must follow the lead of its BRICS peers to ensure that life-saving medicines are affordable. Other BRICS countries have fulfilled the commitments they made in July 2011 to enact public health safeguards spelled out in World Trade Organisation (WTO) agreements. Decisive […]
READ MOREA ‘shocking’ disregard for generics
By Mara Kardas-Nelson This article was originally published in the Mail&Guardian on 15 March 2013. The original is available at http://mg.co.za/article/2013-03-15-a-shocking-disregard-for-generics Many drugs cost far more in South Africa than in countries with strict patent-vetting processes. Two thousand four hundred and forty-two. That’s the number of medicine patents South Africa granted in 2008. In Brazil, […]
READ MOREPhotos of yesterday’s picket
Photographs from the TAC/MSF picket at Gallagher Estate, directed at the Department of Trade and Industry (DTI), can be found here. The picket took place on 26 February 2013 during the DTI’s ‘AFrica IP Forum’.
READ MOREActivists Make Concerns Heard at African IP Forum — Minister Davies Responds —
27 February, MIDRAND – Yesterday, TAC activists picketed at the Africa Intellectual Property (IP) Forum and handed over a memorandum to Rob Davies, Minister of Trade and Industry, before his keynote address. Activists were demanding that the draft IP policy, that will lead to patent law reform, be made public. Minister Davies responded that the […]
READ MORE